RAPP (Rapport Therapeutics) Accumulated Depreciation: $-1.93 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RAPP Rapport Therapeutics Inc RAPP
14 GF Score
Price $42.20
! 3 Warning Signs
View Full Analysis

What is Rapport Therapeutics Accumulated Depreciation?

Rapport Therapeutics RAPP +3.56% 14 Accumulated Depreciation is $-1.93 Mil as of Mar. 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Rapport Therapeutics's quarterly accumulated depreciation increased from Sep. 2025 ($-1.72 Mil) to Dec. 2025 ($-1.98 Mil) but then stayed the same from Dec. 2025 ($-1.98 Mil) to Mar. 2026 ($-1.93 Mil).

Rapport Therapeutics's annual accumulated depreciation increased from Dec. 2023 ($-0.13 Mil) to Dec. 2024 ($-0.97 Mil) and increased from Dec. 2024 ($-0.97 Mil) to Dec. 2025 ($-1.98 Mil).

Rapport Therapeutics Accumulated Depreciation Related Terms

Rapport Therapeutics Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Rapport Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapport Therapeutics Accumulated Depreciation Chart

Rapport Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
-0.02 -0.13 -0.97 -1.98

Rapport Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.21 -1.46 -1.72 -1.98 -1.93
RAPP
14GF Score
Rapport Therapeutics Inc RAPP
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapport Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $-1.93 Mil mean?
Rapport Therapeutics (RAPP) has a Accumulated Depreciation of $-1.93 Mil as of Mar. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Rapport Therapeutics and its competitors.
Is Rapport Therapeutics' Accumulated Depreciation too high?
Rapport Therapeutics' current Accumulated Depreciation is $-1.93 Mil. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Accumulated Depreciation compare to AUPH and PVLA?
Rapport Therapeutics' Accumulated Depreciation of $-1.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Rapport Therapeutics and its competitors. Rapport Therapeutics's current Accumulated Depreciation is $-1.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Accumulated Depreciation of $-1.93 Mil. The current Accumulated Depreciation is $-1.93 Mil. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Accumulated Depreciation is $-1.93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapport Therapeutics Business Description

Address 99 High Street, Suite 2100, Boston, MA, USA, 02110
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score

Get the complete analysis for RAPP

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.20
Price